2023Äê11ÔÂ11ÈÕ£¬Ò½Ñ§Ôº±£ºìÀ¤¸±Ñо¿Ô±¿ÎÌâ×éÔÚFKBP5ͨ¹ýPPAR-¦Ãµ÷¿ØÏßÁ£Ìå×ÔÊÉÔÚËèÇÊÔÙÉú·½ÃæÈ¡µÃÖØÒª½øÕ¹£¬Ñо¿½á¹ûÒÔ¡° FKBP5 activates mitophagy by ablating PPAR-¦Ã to shape a benign remyelination environment¡±ÎªÌ⣬·¢±íÔÚ¹ú¼ÊÖªÃûѧÊõÆÚ¿¯Cell Death & DiseaseÉÏ¡£
¶à·¢ÐÔÓ²»¯Ö¢ÊÇÒ»ÖÖ³£¼ûµÄÖÐÊàÉñ¾ÏµÍ³ÍÑËèÇʼ²²¡£¬Æä·¢²¡ÒòËصĸ´ÔÓÐÔ²¢°éËæ¸ßÖ²ÐÂÊÑÏÖØÓ°Ï컼ÕßµÄÉú»îÖÊÁ¿£¬È»¶øÆ䲡ÒòºÍ»úÖÆÈÔ²»Ã÷È·£¬ÉÐÎÞÓÐЧµÄÖÎÁÆ·½·¨¡£ÏßÁ£Ìå×ÔÊÉͨ¹ý¼õÉÙ»îÐÔÑõ£¨reactive oxygen species, ROS£©ÊÍ·ÅÒÖÖÆÑ×Ö¢·´Ó¦Óе÷½Ú²¢´Ù½øËèÇÊÔÙÉúµÄÖØÒª¹¦ÄÜ¡£»ùÒò×éÊý¾ÝÏÔʾ£¬FKBP5ÊÇÔڶ෢ÐÔÓ²»¯Ö¢²¡ÈËÍâÖÜѪÑùÖмì²âµ½µÄ¸ß±í´ïµ°°×£¬µ«FKBP5ÔÚÆäÖз¢»ÓÔõÑùµÄ×÷ÓÃÈÔ²»Çå³þ¡£
¿ÎÌâ×éÊ×ÏÈÔÚÒ°ÉúÐͺÍFkbp5»ùÒòÇóýÐÍСÊóÖй¹½¨cuprizone (CPZ) ÓÕµ¼µÄÍÑËèÇʶ¯ÎïÄ£ÐÍÖУ¬·¢ÏÖÔÚFkbp5»ùÒòÇóýСÊóÖÐÍÑËèÇʳ̶ÈÃ÷ÏÔµÍÓÚÒ°ÉúÐÍСÊó£»ËæºóÔÚCPZÓÕµ¼µÄÍÑËèÇÊ¿ÉÄ涯ÎïÄ£Ð͵Ä×Ô·¢»Ö¸´ÆÚ·Ö×éʵÑéÖУ¬·¢ÏÖÔÙË軯½ø³ÌÒÀÀµFKBP5µÄ¼¤»î£»¶øÖÐÊàÉñ¾ÏµÍ³ÍÑËèÇʼ²²¡×ÜÊÇ°éË没Ôî´¦¾çÁÒµÄÑ×Ö¢·´Ó¦£¬¸Ã¹ý³ÌÖ÷Ҫͨ¹ýС½ºÖÊϸ°ûºÍÐÇÐνºÖÊϸ°û·¢Éú£¬¿ÎÌâ×é·¢ÏÖFKBP5µÄȱʧÑÏÖØ×è°ÁËÁ½ÖÖ½ºÖÊϸ°ûµÄ¸»¼¯½ø³Ì£»ÎªÁ˲ûÃ÷Æä»úÖÆ£¬¿ÎÌâ×éͨ¹ýRNA-seq¡¢·Ö×Ó¶Ô½Ó¡¢ëÝëÕÌåÄÔÇø¡¢BV2С½ºÖÊϸ°û¡¢Ô´úÉñ¾½ºÖÊϸ°û¼°ºóÐø·Ö×ÓʵÑéϵͳÐÔÑо¿£¬·¢ÏÖÁËFKBP5¶Ô×ÔÊɼ°PINK1/Parkin½éµ¼µÄÏßÁ£Ìå×ÔÊÉͨ·µÄ¼¤»î¶ÔËèÇÊÍÑʧºÍÔÙÉúµÄ½øÕ¹ÖÁ¹ØÖØÒª£¬ÆäÖÐÖØÒªµÄµ÷½ÚÒò×ÓPPAR-¦ÃÊܵ½FKBP5µÄ¸ºµ÷¿Ø£¬×îÖÕ´Ù½øÁËÖÐÊàÉñ¾ÏµÍ³Á¼ÐÔËèÇÊÔÙÉú»·¾³µÄÐγɡ£±¾Ñо¿½ÒʾÁËËèÇʵÄÍÑʧµ½Öð²½ÔÙÉúµÄ¹ý³ÌÐèÒªFKBP5ͨ¹ýÒÖÖÆPPAR-¦Ã¼¤»îÏßÁ£Ìå×ÔÊÉͨ·£¬´Ó¶ø´Ù½øÔÙË軯µÄ½ø³Ì£¬ÌáʾFKBP5ÊÇÖÎÁÆÖÐÉñ¾ÏµÍ³ÍÑËèÇʼ²²¡µÄÖØÒª°Ðµã¡£
ͼ1.£¨A£©ÍÑËèÇʺÍÔÙË軯¶¯ÎïÄ£Ð͹¹½¨Á÷³Ìͼ¡¢£¨B£©¶¯Îïת°ôÐÐΪѧͳ¼Æ¡¢£¨C£©ëÝëÕÌå¼°ÖÜΧ×éÖ¯ÇøÓòµÄLFBȾɫ¡¢MBPÓ«¹âȾɫºÍ͸Éäµç¾µ¹Û²ìËèÇʵĶ¯Ì¬±ä»¯¡¢£¨DºÍE)LFB¡¢MBPµÄIODͳ¼Æ¡¢£¨F)G-ratioͳ¼Æ¡£
Ê®¶þÉúФ×ÊÁÏΪ¸ÃÂÛÎĵĵÚÒ»×÷Õßµ¥Î»£¬Ê®¶þÉúФ×ÊÁÏҽѧԺ˶ʿÑо¿ÉúËïÐË×Ú¡¢Ç®Ãκ®ºÍÀîºêÁÁ¸±Ñо¿Ô±Îª¸ÃÂÛÎĵĹ²Í¬µÚÒ»×÷Õߣ¬Ê®¶þÉúФ×ÊÁϱ£ºìÀ¤¸±Ñо¿Ô±¡¢À¥Ã÷ѧԺ´÷ÀûÀû½²Ê¦¡¢Ê®¶þÉúФ×ÊÁÏÒüÃô¸±Ñо¿Ô±Îª¸ÃÂÛÎĵĹ²Í¬Í¨Ñ¶×÷Õß¡£
¸ÃÑо¿µÃµ½¹ú¼Ò×ÔÈ»¿Æѧ»ù½ðί¡¢ÔÆÄÏÊ¡¿Æ¼¼ÌüµÈ¿ÆѧÑо¿»ù½ðÏîÄ¿µÄ¹²Í¬×ÊÖú¡£ÂÛÎÄÁ´½Óhttps://doi.org/10.1038/s41419-023-06260-7¡£
¹©¸å£ºÒ½Ñ§Ôº
±à¼£ºÀîÕÜ ÔðÈα༣º³ÂÌÎ
